MiR-378a-3p was found to be downregulated in prostate cancer, and miR-378a-3p was revealed to reduce SLC2A1 expression to interfere with glycolytic pathway and cell proliferation (Cannistraci et al., 2022). Here, SLC2A1 is linked to Familial prostate cancer.